<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00027430</url>
  </required_header>
  <id_info>
    <org_study_id>FD-R-1981-01</org_study_id>
    <secondary_id>FD-R-001981-01</secondary_id>
    <nct_id>NCT00027430</nct_id>
  </id_info>
  <brief_title>Androgen Replacement Therapy in Women With Hypopituitarism</brief_title>
  <official_title>TheraDerm Administration in Women With Hypopituitarism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>FDA Office of Orphan Products Development</source>
  <brief_summary>
    <textblock>
      This is a study to determine whether testosterone replacement with TheraDerm can improve bone&#xD;
      density, mood, sex drive, thinking, and distribution of body fat and muscle mass in women&#xD;
      with hypopituitarism.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will be randomized into 2 groups to receive testosterone replacement therapy or&#xD;
      placebo. Group 1 will receive 2 testosterone patches and estrogen pills for 12 months. Group&#xD;
      2 will receive 2 placebo patches and estrogen pills for 12 months. Changes in bone density,&#xD;
      bone metabolism markers, body composition, libido, and quality of life will be compared in&#xD;
      the women receiving testosterone replacement therapy with that of the women receiving&#xD;
      placebo.&#xD;
&#xD;
      Completion date provided represents the completion date of the grant per OOPD records&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2001</start_date>
  <completion_date>December 2004</completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Hypopituitarism</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TheraDerm</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Hypogonadism and/or hypoadrenalism of central origin&#xD;
&#xD;
          -  Testosterone or free testosterone level below the median for age-matched normal&#xD;
             controls&#xD;
&#xD;
          -  Prior estrogen preparation for at least 6 months&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Any disease known to affect bone metabolism, including untreated hypothyroidism or&#xD;
             hyperthyroidism&#xD;
&#xD;
          -  Change in thyroid hormone dose in the last 3 months&#xD;
&#xD;
          -  Untreated Cushing's syndrome&#xD;
&#xD;
          -  Renal failure&#xD;
&#xD;
          -  Alcoholism&#xD;
&#xD;
          -  Anorexia nervosa&#xD;
&#xD;
          -  Prior use of medication known to affect bone metabolism (e.g., supraphysiologic doses&#xD;
             of glucocorticoids, phenytoin, bisphosphonates, or calcitonin) within the past 3&#xD;
             months&#xD;
&#xD;
          -  Pregnant or nursing&#xD;
&#xD;
          -  Uncontrolled hypertension&#xD;
&#xD;
          -  ALT greater than 3 times upper limit of normal&#xD;
&#xD;
          -  Serum creatinine greater than 2 times the upper limit of normal&#xD;
&#xD;
          -  Any contraindication to estrogen therapy, including history of breast cancer or&#xD;
             undiagnosed uterine bleeding&#xD;
&#xD;
          -  Concurrent growth hormone replacement therapy, if patient has been receiving it for&#xD;
             less than 2 years&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anne Klibanski, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2001</verification_date>
  <study_first_submitted>December 5, 2001</study_first_submitted>
  <study_first_submitted_qc>December 6, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 7, 2001</study_first_posted>
  <last_update_submitted>March 24, 2015</last_update_submitted>
  <last_update_submitted_qc>March 24, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 25, 2015</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypopituitarism</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

